Therapeutic Index (TI) of
Antibody-drug Conjugates (ADCs)
ADCs
are often considered to extend the therapeutic index of their payloads.
Conjugation of the drug to an antibody can reduce the minimum effective dose
(MED) of the drug and increase the maximum tolerated dose (MTD).
When
comparing small molecule chemotherapeutic drugs with the ADC, it is important
to understand the difference in exposure kinetics between the two. Some
researchers have proposed an exposure-based model to calculate TIs. By
employing an exposure-based TI calculation approach, we can easily explain the
improvement in anti-tumor activities of TI-improved ADCs and capture the
emerging success of second-generation ADCs in the clinic.
Creative
Diagnostics provides a series of monoclonal and polyclonal antibodies against
different small molecule chemotherapeutic drugs in ADCs. These anti-drug
antibodies are valuable tools to facilitate the TI analysis of newly developed
ADCs bearing these drugs.
Key
Features:
● Suitable
for PK and safety evaluation of newly developed ADCs
● Good
sensitivity and stability
● A
comprehensive range of antibodies & kits
Fig.1 Anti-MMAE Mab Affinity Curves. (CABT-B8992) | Fig.2
ELISA binding of Anti-Doxorubicin Mab
(CABT-L3221) with doxorubicin |
Product
List
Anti-Payloads
Antibodies
Quantitative Assays for ADCs
